MoonLake Immunotherapeutics (MLTX) Q4 2025 earnings summary

Executive summary

• Positive topline results from the Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA), with over 80% of patients achieving ASAS40 by week 12.

• Clinical, imaging, and biomarker data confirm rapid and meaningful reduction in inflammation and osteoblast activity, suggesting potential for disease modification.

• Sonelokimab (SLK) demonstrated consistent safety, with no new signals detected.

• SLK now has positive data in five indications across Phase 2 and 3 trials.

Financial highlights

• Ended Q4 2025 with $394 million in cash, cash equivalents, and short-term marketable debt securities.

• Research and development expenses for Q4 2025 were $56.0 million, down from $60.6 million in the previous quarter.

• General and administrative expenses for Q4 2025 were $9.2 million, down from $10.8 million sequentially.

• Recent equity raise brought in gross proceeds of $75 million.

Outlook and guidance

• Cash runway expected to extend into the second half of 2027.

• Up to $400 million in non-dilutive funds remain available via amended debt facility.

• Key 2026 catalysts include data from Phase 3 trials in hidradenitis suppurativa (HS), psoriatic arthritis (PSA), and palmoplantar pustulosis (PPP).

• BLA submission for HS anticipated in H2 2026.